BioCentury | Mar 25, 2015
Company News

Management tracks

...San Jose, Calif.) hired Paul-Andre de Lame as CMO. He was co-founder and CMO of Cardiokine Inc....
BioCentury | Nov 5, 2012
Clinical News

Lixivaptan regulatory update

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Nov 2, 2012
Company News

Cornerstone receives lixivaptan complete response

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Sep 17, 2012
Clinical News

Lixivaptan regulatory update

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Sep 12, 2012
Company News

FDA reviewer gives mixed recommendation on lixivaptan

...has an Oct. 29 PDUFA date. Cornerstone, which gained lixivaptan through its January acquisition of Cardiokine Inc....
BioCentury | Jul 30, 2012
Clinical News

Lixivaptan regulatory update

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Jul 25, 2012
Company News

FDA to discuss Cornerstone's lixivaptan

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Mar 19, 2012
Clinical News

Lixivaptan regulatory update

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Mar 14, 2012
Company News

FDA to review CRTX 080 for hyponatremia

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Jan 9, 2012
Company News

Cardiokine, Cornerstone Therapeutics deal

...Cornerstone acquired cardiovascular disease company Cardiokine. Cardiokine shareholders will receive $27.3 million in cash up front...
...sales milestones for hyponatremia compound lixivaptan , plus 8% or 12% royalties, depending on labeling. Cardiokine...
...in 1Q13. Cornerstone said the label could include claims for euvolemic hyponatremia, in which case Cardiokine...
Items per page:
1 - 10 of 48
BioCentury | Mar 25, 2015
Company News

Management tracks

...San Jose, Calif.) hired Paul-Andre de Lame as CMO. He was co-founder and CMO of Cardiokine Inc....
BioCentury | Nov 5, 2012
Clinical News

Lixivaptan regulatory update

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Nov 2, 2012
Company News

Cornerstone receives lixivaptan complete response

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Sep 17, 2012
Clinical News

Lixivaptan regulatory update

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Sep 12, 2012
Company News

FDA reviewer gives mixed recommendation on lixivaptan

...has an Oct. 29 PDUFA date. Cornerstone, which gained lixivaptan through its January acquisition of Cardiokine Inc....
BioCentury | Jul 30, 2012
Clinical News

Lixivaptan regulatory update

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Jul 25, 2012
Company News

FDA to discuss Cornerstone's lixivaptan

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Mar 19, 2012
Clinical News

Lixivaptan regulatory update

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Mar 14, 2012
Company News

FDA to review CRTX 080 for hyponatremia

...gained the selective vasopressin V2 receptor antagonist through its January acquisition of cardiovascular disease company Cardiokine Inc....
BioCentury | Jan 9, 2012
Company News

Cardiokine, Cornerstone Therapeutics deal

...Cornerstone acquired cardiovascular disease company Cardiokine. Cardiokine shareholders will receive $27.3 million in cash up front...
...sales milestones for hyponatremia compound lixivaptan , plus 8% or 12% royalties, depending on labeling. Cardiokine...
...in 1Q13. Cornerstone said the label could include claims for euvolemic hyponatremia, in which case Cardiokine...
Items per page:
1 - 10 of 48